-
1.发明授权Combination comprising a signal transduction inhibitor and an epothilone derivative 失效包含信号转导抑制剂和埃坡霉素衍生物的组合公开(公告)号：US07723339B2
公开(公告)日：2010-05-25
申请号：US10469367
申请日：2002-02-26
申请人： Ralf Brandt , Elisabeth Buchdunger , Carl-Henrik Heldin , Arne Östman , Kristian Pietras , Terence O'Reilly , John D Rothermel , Peter Traxler , Markus Wartmann
发明人： Ralf Brandt , Elisabeth Buchdunger , Carl-Henrik Heldin , Arne Östman , Kristian Pietras , Terence O'Reilly , John D Rothermel , Peter Traxler , Markus Wartmann
IPC分类号： A61K31/497 , A61K31/425 , A01N43/78 , A01N43/54 , C07D239/42 , C07D401/04 , A61K31/435 , A01N43/40 , A61K31/505
CPC分类号： A61K31/505 , A61K31/425 , A61K45/06 , A61K31/435 , A61K2300/00
摘要： The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.
摘要翻译： 本发明涉及包含N- {5- [4-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺和环硫代 衍生物; 包含所述组合的药物组合物; 包括所述组合的处理方法; 以及包括所述组合的商业包装。
-
公开(公告)号：US06699843B2
公开(公告)日：2004-03-02
申请号：US09859724
申请日：2001-05-17
IPC分类号： A61K3170
CPC分类号： C40B50/04 , A61K38/00 , A61K47/544 , A61K47/547 , A61K47/549 , A61K47/60 , A61K48/00 , B82Y5/00 , C07H19/06 , C07H19/10 , C07H21/00 , C07K14/001 , C07K14/47 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/52 , C12N9/1276 , C12N15/1048 , C12N15/1136 , C12N15/115 , C12N2310/13 , C12N2310/317 , C12N2310/3183 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/3515 , C12N2310/53 , C12Q1/37 , C12Q1/6811 , C40B40/00 , F02B2075/027 , G01N33/531 , G01N33/532 , G01N33/535 , G01N33/56988 , G01N33/68 , G01N33/6842 , G01N33/76 , G01N2333/16 , G01N2333/163 , G01N2333/503 , G01N2333/575 , G01N2333/62 , G01N2333/8125 , G01N2333/96433 , G01N2333/96436 , G01N2333/96455 , G01N2333/96486 , G01N2333/966 , G01N2333/9726 , G01N2333/974 , G01N2333/976 , C12N2310/3521 , C12Q2525/101 , C12Q2525/301 , C12Q2541/101
摘要： A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
摘要翻译： 提供了治疗实体瘤的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。 在优选的实施方案中，使用SELEX方法鉴定了用于通过指数浓缩的配体的系统演化的PDGF适体。 还提供了用于降低实体瘤的组织液压（IFP）的方法，包括施用PDGF适体。 最后，提供了一种增加细胞毒剂到肿瘤中的摄取的方法，包括给予包含PDGF适体和细胞毒性剂的组合物。
-
公开(公告)号：US06974816B2
公开(公告)日：2005-12-13
申请号：US10227081
申请日：2002-08-23
CPC分类号： A61K48/0008
摘要： The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.
摘要翻译： 本发明涉及（a）血小板衍生生长因子（PDGF）活性抑制剂和（b）血管内皮生长因子（VEGF-，特别是VEGF-C）基因转移载体的组合，包含（ a）和（b）与药学上可接受的载体材料的组合; 包含如上定义的（a）和（b）和任选的药学上可接受的载体材料的产品，用于同时，按时间顺序交错或分开使用; 施用或使用所述组合或产品来治疗内皮损伤的方法; 和/或（a）和（b）用于制造用于治疗内皮损伤的所述药物制剂或产品的用途。
-
-
搜索结果
3 条记录 (耗时 0.032 秒)
